IO Biotech

IOBTQ · NASDAQ

$0.0001+$0.00 (+0.00%)TodayMarket closed · Oct 23, 1:18 PM ET

No price history for this range.

About IOBTQ

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees: 80
Headquarters: COPENHAGEN
Listed: Nov 5, 2021
Sector: Health Care
Industry: Biotechnology
Website: iobiotech.com

Leadership

IO Biotech executives
Name	Title	Since	Age
Peter Hirth	—	—	73
Mai-Britt Zocca	—	2015	57
Amy Sullivan	—	—	55
Devin Smith	—	—	57
Qasim Ahmad	—	—	54
Faical Miyara	—	—	—
Helen Collins	—	—	63
Christian Elling	—	—	56
Kathleen Glaub	—	—	71
Heidi Hunter	—	—	67
David Smith	—	—	65

Similar companies

Companies in the same industry as IO Biotech

EVAXEvaxion A/S$3.76+1.35%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.